Celsus Therapeutics Overview

  • Year Founded
  • 2004

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $20.3M

Celsus Therapeutics General Information

Description

Developer of non-steroidal, synthetic anti-inflammatory drugs. The company a biopharmaceutical drug enterprise developing synthetic anti-inflammatory drugs termed Multi-Functional Anti-Inflammatory Drugs (MFAID), that serve as an alternative to corticosteroids. The company is developing therapies to address respiratory inflammatory diseases (Allergic Rhinitis and Asthma), inflammatory skin diseases (dermatitis), inflammatory bowel disease (IBD), ophthalmic inflammatory conditions (conjunctivitis and dry eye), and Cystic Fibrosis.

Contact Information

Formerly Known As
Morria Biopharmaceuticals
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • The Gridiron Building
  • One Pancras Square
  • London N1C 4AG
  • England, United Kingdom
+44 020
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • The Gridiron Building
  • One Pancras Square
  • London N1C 4AG
  • England, United Kingdom
+44 020

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Celsus Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Merger/Acquisition 18-Sep-2015 $20.3M Completed Generating Revenue
8. Secondary Transaction - Open Market 31-Mar-2014 Completed Generating Revenue
7. 2PO 30-Jan-2014 Completed Generating Revenue
6. IPO 12-Dec-2013 Completed Generating Revenue
5. Secondary Transaction - Open Market 06-Nov-2013 Completed Generating Revenue
4. PIPE 30-Sep-2013 Completed Generating Revenue
3. Secondary Transaction - Open Market 16-Apr-2013 Completed Generating Revenue
2. Later Stage VC 01-Feb-2013 $2.43M $5.63M Completed Generating Revenue
1. Early Stage VC 10-May-2007 $3.19M $3.19M Completed Startup
To view Celsus Therapeutics’s complete valuation and funding history, request access »

Celsus Therapeutics Former Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
Alpha Capital Partners PE/Buyout Minority
Baker Brothers Investments Hedge Fund Minority
Capital Ventures International Hedge Fund Minority
Charles Street Securities Europe Venture Capital Minority
Franklin Templeton Asset Manager Minority
You’re viewing 5 of 7 investors. Get the full list »

Celsus Therapeutics Acquisitions (1)

Celsus Therapeutics’s most recent deal was a Reverse Merger with Akari Therapeutics. The deal was made on 18-Sep-2015.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Akari Therapeutics 18-Sep-2015 Reverse Merger Drug Discovery
To view Celsus Therapeutics’s complete acquisitions history, request access »

Celsus Therapeutics FAQs

  • When was Celsus Therapeutics founded?

    Celsus Therapeutics was founded in 2004.

  • Where is Celsus Therapeutics headquartered?

    Celsus Therapeutics is headquartered in London, United Kingdom.

  • What industry is Celsus Therapeutics in?

    Celsus Therapeutics’s primary industry is Drug Discovery.

  • Is Celsus Therapeutics a private or public company?

    Celsus Therapeutics is a Private company.

  • What is the current valuation of Celsus Therapeutics?

    The current valuation of Celsus Therapeutics is .

  • What is Celsus Therapeutics’s current revenue?

    The current revenue for Celsus Therapeutics is .

  • How much funding has Celsus Therapeutics raised over time?

    Celsus Therapeutics has raised $30.7M.

  • Who are Celsus Therapeutics’s investors?

    Alpha Capital Partners, Baker Brothers Investments, Capital Ventures International, Charles Street Securities Europe, and Franklin Templeton are 5 of 7 investors who have invested in Celsus Therapeutics.

  • When was Celsus Therapeutics acquired?

    Celsus Therapeutics was acquired on 18-Sep-2015.

  • Who acquired Celsus Therapeutics?

    Celsus Therapeutics was acquired by Akari Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process